Stock Track | Intellia Therapeutics Soars 5.06% Intraday on Multiple Analyst Upgrades and ARK Invest Buying

Stock Track

Apr 28

Intellia Therapeutics (NTLA) stock soared 5.06% during intraday trading on Tuesday, reflecting strong positive momentum in the market.

The significant price increase appears to be driven by a combination of bullish analyst actions and notable institutional buying interest. Multiple research firms have raised their price targets for the gene-editing company, while Cathie Wood's ARK Invest executed purchases of the stock.

Specifically, Canaccord Genuity raised its target price to $58 from $48, Leerink Partners increased its target to $35 from $29, Citizens lifted its target to $30 from $28, and Chardan raised its target to $30 from $27. These analyst upgrades, combined with ARK Invest's strategic purchase of Intellia shares, have generated positive sentiment among investors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1120558250"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120558250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120558250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120558250","market":"us","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Soars 5.06% Intraday on Multiple Analyst Upgrades and ARK Invest Buying","media":"Stock Track","content":"<p>Intellia Therapeutics (NTLA) stock soared 5.06% during intraday trading on Tuesday, reflecting strong positive momentum in the market.</p><p>The significant price increase appears to be driven by a combination of bullish analyst actions and notable institutional buying interest. Multiple research firms have raised their price targets for the gene-editing company, while Cathie Wood's ARK Invest executed purchases of the stock.</p><p>Specifically, Canaccord Genuity raised its target price to $58 from $48, Leerink Partners increased its target to $35 from $29, Citizens lifted its target to $30 from $28, and Chardan raised its target to $30 from $27. These analyst upgrades, combined with ARK Invest's strategic purchase of Intellia shares, have generated positive sentiment among investors.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Soars 5.06% Intraday on Multiple Analyst Upgrades and ARK Invest Buying</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Soars 5.06% Intraday on Multiple Analyst Upgrades and ARK Invest Buying\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-28 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics (NTLA) stock soared 5.06% during intraday trading on Tuesday, reflecting strong positive momentum in the market.</p><p>The significant price increase appears to be driven by a combination of bullish analyst actions and notable institutional buying interest. Multiple research firms have raised their price targets for the gene-editing company, while Cathie Wood's ARK Invest executed purchases of the stock.</p><p>Specifically, Canaccord Genuity raised its target price to $58 from $48, Leerink Partners increased its target to $35 from $29, Citizens lifted its target to $30 from $28, and Chardan raised its target to $30 from $27. These analyst upgrades, combined with ARK Invest's strategic purchase of Intellia shares, have generated positive sentiment among investors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1120558250","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120558250","pubTimestamp":1777385355,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics (NTLA) stock soared 5.06% during intraday trading on Tuesday, reflecting strong positive momentum in the market.The significant price increase appears to be driven by a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"个股追踪|Intellia Therapeutics盘中大涨5.06%，多位分析师上调评级及ARK Invest买入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics (NTLA) stock soared 5.06% during intraday trading on Tuesday, reflecting strong positive momentum in the market.The significant price increase appears to be driven by a combination of bullish analyst actions and notable institutional buying interest. Multiple research firms have raised their price targets for the gene-editing company, while Cathie Wood's ARK Invest executed purchases of the stock.Specifically, Canaccord Genuity raised its target price to $58 from $48, Leerink Partners increased its target to $35 from $29, Citizens lifted its target to $30 from $28, and Chardan raised its target to $30 from $27. These analyst upgrades, combined with ARK Invest's strategic purchase of Intellia shares, have generated positive sentiment among investors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}